Among them, ABT-199, a selective Bcl-2 inhibitor, has demonstrated potent efficacy in preclinical models of CLL and NHL characterized by Bcl-2 overexpression, without inducing thrombocytopenia 31. The gene discussed is BCL2; the disease is non-Hodgkin lymphoma.